Korean Biotech ETFs Post Losses Up to -21.18% Amid Rate Rises and Novartis Failures
Korean biotech ETFs recorded significant losses over the recent one-month period, with UNICORN K Bio Active posting the steepest decline at -21.18% among all ETFs excluding leveraged and inverse products. Rising interest rates, increased capital flows into semiconductor stocks, and clinical trial
GateMacroTradfiHub·09-10 05:03
